keyword
MENU ▼
Read by QxMD icon Read
search

mirtazapine insomnia

keyword
https://www.readbyqxmd.com/read/30194544/other-antidepressants
#1
T E Schwasinger-Schmidt, M Macaluso
This chapter addresses the following FDA-approved medications for the treatment of major depressive disorder available for use in the United States including bupropion, mirtazapine, trazodone, vortioxetine, and vilazodone. These medications do not belong to one of the previously featured classes of antidepressants discussed in the preceding chapters. Each medication featured in this chapter has a unique structure and properties that target diverse receptors in the central nervous system. These diverse targets are distinct from other classes of medications used to treat major depressive disorder...
September 8, 2018: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/30168031/orthorexia-nervosa-and-comorbid-depression-successfully-treated-with-mirtazapine-a-case-report
#2
Rui Lopes, Raquel Melo, Bernardo Dias Pereira
Orthorexia nervosa (ON) is a recently proposed eating disordered behaviour characterized by an obsessional or exaggerated fixation on healthy eating. The published literature is scarce regarding its classification, clinical presentation, management and long-term outcomes. Herein, we present the clinical and follow-up findings of an 18-year-old woman with ON comorbid with depression, successfully treated with mirtazapine. The patient had a 12-month history of obsessional behaviours for "healthy food", characterized by suppression of sugar and fat from her diet, tightly counted meal calorie content, eating only self-made meals, avoidance of eating in public, unacceptance of other person's opinions on diet, social isolation and a weight loss of 15 kg (body mass index of 16...
August 28, 2018: Eating and Weight Disorders: EWD
https://www.readbyqxmd.com/read/30113101/what-do-we-know-about-the-pharmacotheraputic-management-of-insomnia-in-cannabis-withdrawal-a-systematic-review
#3
REVIEW
Naista Zhand, Robert Milin
BACKGROUND AND OBJECTIVES: Sleep disturbance is one of the hallmarks of cannabis withdrawal. Studies have indicated that treatment of this key symptom may facilitate abstinence. In the present paper we aim to provide a systematic review of the extant literature on pharmacological management of sleep disturbance associated with cannabis withdrawal. METHOD: We conducted a systematic literature search across five electronic databases including PubMed, Psycinfo, MEDLINE, Cochrane review and Embase...
September 2018: American Journal on Addictions
https://www.readbyqxmd.com/read/29734995/effective-treatment-of-insomnia-with-mirtazapine-attenuates-concomitant-suicidal-ideation
#4
Kamal Gandotra, Peijun Chen, George E Jaskiw, P Eric Konicki, Kingman P Strohl
No abstract text is available yet for this article.
May 15, 2018: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/29678261/mirtazapine
#5
REVIEW
Abdulrahman Al-Majed, Ahmed H Bakheit, Raed M Alharbi, Hatem A Abdel Aziz
Mirtazapine is one of antidepression which is used mainly in the treatment of depression, moreover, it is sometimes used in the treatment of anxiety disorders, insomnia, nausea, and vomiting, and to produce weight gain when desirable. The action of mirtazapine is an antagonist of certain adrenergic and serotonin receptors, and, furthermore, the drug is used strong as antihistamine, and it is occasionally defined as a noradrenergic and specific serotonergic antidepressant (NaSSA). The comprehensive profile of mirtazapine gives more detailed information about nomenclature, formulae, elemental analysis, and appearance...
2018: Profiles of Drug Substances, Excipients, and related Methodology
https://www.readbyqxmd.com/read/29499579/-sleep-disorders-and-impaired-sleep-as-adverse-drug-reactions-of-psychotropic-drugs-an-evaluation-of-data-of-summaries-of-product-characteristics
#6
Maximilian Gahr, Bernhard J Connemann, René Zeiss, Albrecht Fröhlich
OBJECTIVE: Psychopharmacotherapy is essential in the treatment of many mental disorders. Adverse drug reactions (ADR) have impact on compliance and tolerability. Sleep disorders or impaired sleep may occur as ADRs of psychopharmacotherapy. Sleep disorders are associated with an increased risk for physical and mental illness and may impair cognition, impulse control, emotion regulation and mood. Objective of the following study was the systematic presentation of type and risk of sleep disorders/impairments of sleep of frequently prescribed psychotropic drugs...
July 2018: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/29487083/drugs-for-insomnia-beyond-benzodiazepines-pharmacology-clinical-applications-and-discovery
#7
REVIEW
Tobias Atkin, Stefano Comai, Gabriella Gobbi
Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have many side effects, including cognitive impairment, tolerance, rebound insomnia upon discontinuation, car accidents/falls, abuse, and dependence liability. Consequently, the clinical use of off-label drugs and novel drugs that do not target the GABAergic system is increasing. The purpose of this review is to analyze the neurobiological and clinical evidence of pharmacological treatments of insomnia, excluding the BZDs and Z-drugs...
April 2018: Pharmacological Reviews
https://www.readbyqxmd.com/read/29472752/low-dose-mirtazapine-induced-nightmares-necessitating-its-discontinuation-in-a-young-adult-female
#8
Vikas Menon, Pravallika Madhavapuri
Mirtazapine is a novel tetracyclic antidepressant which enhances noradrenergic and serotonergic transmission by blocking central α2-adrenergic auto- and hetero-receptors. Due to favorable safety and adverse effect profile, it is often viewed as a promising agent for treatment of depression. Particularly, its anxiolytic and sleep-improving properties have led to its favorable positioning for the management of depression with insomnia. Our objective is to describe a case of depression with treatment-emergent nightmares induced by mirtazapine...
October 2017: Journal of Pharmacology & Pharmacotherapeutics
https://www.readbyqxmd.com/read/29185897/pharmacological-treatment-of-insomnia-symptoms-in-individuals-with-substance-use-disorders-in-spain-a-quasi-experimental-study
#9
L Grau-López, L Grau-López, C Daigre, R F Palma-Álvarez, L Rodriguez-Cintas, E Ros-Cucurull, C Roncero
INTRODUCTION: Pharmacological treatment of insomnia in patients with addictions has been hardly investigated and there are few researches about it in an inpatient detoxification. The aim of this study was to describe the outcomes of the pharmacological treatment of insomnia in SUD patients admitted to a detoxification unit in Spain, with a focus on the primary substance of abuse and co-occurring mental disorders. METHODS: A quasi-experimental study was conducted in 481 addicted in patients, who were admitted for substances detoxification in Vall d´Hebron University Hospital, Barcelona, Spain, from 2010 to 2015...
July 3, 2018: Substance Use & Misuse
https://www.readbyqxmd.com/read/28822709/the-influence-of-antidepressants-on-restless-legs-syndrome-and-periodic-limb-movements-a-systematic-review
#10
REVIEW
Bhanu Prakash Kolla, Meghna P Mansukhani, J Michael Bostwick
Restless legs syndrome is commonly co-morbid with medical conditions that are treated with antidepressant medications, such as depression, anxiety, fibromyalgia, and chronic insomnia disorder. Evidence from case reports and cross-sectional studies suggests that antidepressants may induce or worsen restless legs syndrome and increase periodic limb movements. We undertook a systematic review of the literature to identify and collate all prospective studies that measured restless legs syndrome symptoms and/or periodic limb movements following the introduction of an antidepressant...
April 2018: Sleep Medicine Reviews
https://www.readbyqxmd.com/read/28791566/effects-of-antidepressants-on-sleep
#11
REVIEW
Adam Wichniak, Aleksandra Wierzbicka, Małgorzata Walęcka, Wojciech Jernajczyk
PURPOSE OF REVIEW: The aim of this review article was to summarize recent publications on effects of antidepressants on sleep and to show that these effects not only depend on the kind of antidepressant drugs but are also related to the dose, the time of drug administration, and the duration of the treatment. RECENT FINDINGS: Complaints of disrupted sleep are very common in patients suffering from depression, and they are listed among diagnostic criteria for this disorder...
August 9, 2017: Current Psychiatry Reports
https://www.readbyqxmd.com/read/28702268/distressing-visual-hallucinations-after-treatment-with-trazodone
#12
Gustavo Santos, Ana Maria Moreira
Trazodone, a second-generation atypical antidepressant, is increasingly being used off-label, in the treatment of insomnia. Although generally well tolerated, trazodone treatment can be associated with some complications. We describe a case of a 60-year-old man who received trazodone for primary insomnia. He returned, to the emergency department, two days later with distressing visual hallucinations, which prompted inpatient treatment. Trazodone was discontinued, leading to a complete resolution of his visual hallucinations, and he was treated with mirtazapine for 6 months...
2017: Case Reports in Psychiatry
https://www.readbyqxmd.com/read/28093029/low-doses-of-mirtazapine-or-quetiapine-for-transient-insomnia-a-randomised-double-blind-cross-over-placebo-controlled-trial
#13
RANDOMIZED CONTROLLED TRIAL
Julie Karsten, Loes A Hagenauw, Jeanine Kamphuis, Marike Lancel
Low doses of the antidepressant mirtazapine or the neuroleptic quetiapine are often prescribed off-label for insomnia. However, studies on the effects on sleep and hangover effects the following day are scarce. In this randomised, double-blind, cross-over, placebo-controlled trial, the influence of 7.5 mg mirtazapine and 50 mg quetiapine on both normal sleep and sleep disturbed by acoustic stress (traffic noise) as a model for transient insomnia was assessed. Additionally, hangover effects on next-day alertness and cognitive functioning were examined...
March 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27807450/trazodone-addition-to-paroxetine-and-mirtazapine-in-a-patient-with-treatment-resistant-depression-the-pros-and-cons-of-combining-three-antidepressants
#14
Rui Lopes, José Carlos Alves, Raquel Garcia Rego
Dual antidepressant combination for treatment-resistant depression is a strategy well supported by literature and accepted in clinical practice. Rather, the usefulness of the combination of more than two antidepressants is controversial. This may be related to the possibility of higher side-effect burden and to doubts about its pharmacological effectiveness and therapeutic advantage compared to other standard treatment options. We report a relapse of moderate-to-severe depressive symptoms with insomnia that successfully remitted after the addition of trazodone to a dual combination of paroxetine and mirtazapine (in standard effective doses) in a patient with treatment-resistant depression...
2016: Case Reports in Medicine
https://www.readbyqxmd.com/read/27482970/a-phase-2-randomized-dose-finding-study-with-esmirtazapine-in-patients-with-primary-insomnia
#15
RANDOMIZED CONTROLLED TRIAL
Frank Ruwe, Pieta IJzerman-Boon, Thomas Roth, Gary Zammit, Neely Ivgy-May
The antidepressant mirtazapine is an alternative to classical hypnotics, and this study investigated the efficacy and safety of esmirtazapine (Org 50081, the maleic acid salt of S-mirtazapine) in patients given a diagnosis of primary insomnia after acute (2-day) treatment. Patients aged 18 to 65 years with primary insomnia were randomized to receive placebo or 1.5-, 3.0-, or 4.5-mg esmirtazapine in a balanced 4-way crossover study; 2 sleep laboratory nights with polysomnography were separated by 5-day, single-blind placebo washout periods...
October 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27433364/bupropion-induced-hyponatremia-in-an-elderly-patient-a-case-report-and-review-of-the-literature
#16
Sahil Munjal, Yvette Smolin
We present the case of a 72-year-old female with a major depressive episode who developed hyponatremia associated with bupropion. In reviewing the literature, there are only a few case reports which pertain to this topic. The clinical symptoms of hyponatremia can be misinterpreted as a worsening of the primary psychiatric illness and can lead to potentially serious consequences if not fully evaluated. We recommend that clinicians should be well aware of this side effect and that sodium levels should be checked within the first 2 weeks after initiating treatment in patients, especially those with additional risk factors for hyponatremia, such as older age, female sex, diuretic use, low BMI, and unexplained mental status changes at any time during treatment with antidepressants...
2016: Case Reports in Psychiatry
https://www.readbyqxmd.com/read/27004670/antidepressants-in-parkinson-s-disease-recommendations-by-the-movement-disorder-study-group-of-the-neurological-association-of-madrid
#17
E Peña, M Mata, L López-Manzanares, M Kurtis, M Eimil, J C Martínez-Castrillo, I Navas, I J Posada, C Prieto, C Ruíz-Huete, L Vela, B Venegas
INTRODUCTION: Although antidepressants are widely used in Parkinson's disease (PD), few well-designed studies to support their efficacy have been conducted. DEVELOPMENT: These clinical guidelines are based on a review of the literature and the results of an AMN movement disorder study group survey. CONCLUSIONS: Evidence suggests that nortriptyline, venlafaxine, paroxetine, and citalopram may be useful in treating depression in PD, although studies on paroxetine and citalopram yield conflicting results...
March 19, 2016: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/26873652/mirtazapine-in-orodispersible-form-for-patients-with-preoperative-psychological-distress-a-pilot-study
#18
Wei-Han Chou, Feng-Sheng Lin, Chih-Peng Lin, Wen-Ying Lin, Jr-Chi Yie, Wei-Zen Sun
BACKGROUND: Perioperative psychological distress is associated with preoperative anxiety, depression, and postoperative pain. Mirtazapine is effective as an antidepressant, anxiolytic agent, and sleep enhancer. Moreover, mirtazapine can be made as orodispersible tablets with a fast onset for patients in nil per os status. This study is to determine whether mirtazapine can help psychologically distressed patients reduce perioperative anxiety, depression, and postoperative pain. MATERIALS AND METHODS: Patients with preoperative psychological distress, undergoing major abdominal surgery, were inquired and assigned to two groups according to their own choice...
March 2016: Acta Anaesthesiologica Taiwanica: Official Journal of the Taiwan Society of Anesthesiologists
https://www.readbyqxmd.com/read/26856810/pharmacology-for-sleep-disturbance-in-ptsd
#19
Gosia Lipinska, David S Baldwin, Kevin G F Thomas
Symptoms of sleep disturbance, particularly nightmares and insomnia, are a central feature of post-traumatic stress disorder (PTSD). Emerging evidence suggests that specific treatment of PTSD-related sleep disturbance improves other symptoms of the disorder, which in turn suggests that such disturbance may be fundamental to development and maintenance of the disorder. This mini-review focuses on pharmacological treatment of sleep disturbance in adult PTSD (specifically, studies testing the efficacy of antidepressants, adrenergic inhibiting agents, antipsychotics and benzodiazepine and non-benzodiazepine hypnotics)...
March 2016: Human Psychopharmacology
https://www.readbyqxmd.com/read/26813241/early-improvements-in-individual-symptoms-to-predict-later-remission-in-major-depressive-disorder-treated-with-mirtazapine
#20
RANDOMIZED CONTROLLED TRIAL
Kei Funaki, Shinichiro Nakajima, Takefumi Suzuki, Masaru Mimura, Hiroyuki Uchida
Few studies, to our knowledge, have examined whether early improvements in individual, instead of overall, depressive symptoms predict remission in major depressive disorder (MDD). This post hoc analysis used data from 194 patients with MDD enrolled in a 6-week double-blind, placebo-controlled, randomized trial of mirtazapine, to identify improvements in specific individual depressive symptoms in the early phase that are associated with subsequent remission. Trajectories of individual depressive symptoms over 6 weeks were compared between remitters and nonremitters...
September 2016: Journal of Clinical Pharmacology
keyword
keyword
162222
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"